BNCM | DELEX Merger

Menu
Get In Touch

Human Albumin – Humal

HUMAL is manufactured by “Fortune Global 500” company in India, considered the largest in the private sector. It was launched by Delex Pharma in October 2014. The said critical care brand is available in select Mercury Drug branches and 50 private & government hospitals nationwide.

JMN Brothers Pharma Limited Inc.

JMN Brothers Pharma Limited Inc. March 18, 2025 admin_bncm 2:45 am JMN Brothers Pharma Limited Inc. JMN Brothers Pharma Limited, Inc., a subsidiary company of Delex Pharma, was founded in the Philippines on June 27, 2016, by the management heading the latter organization. Although it is a new player in the market, it has slowly made rounds to become one of the trusted companies in the country, focusing on women’s health and ethical products.  While JMN Pharma strives to bring premier and affordable pharmaceutical products to the Philippine market, it has forged partnerships with credible WHO-GMP-compliant local and multinational manufacturing companies. Hence, it boosts the highest ethical standard of the company in the pharmaceutical field. Moreover, the various Intensive Care Unit (ICU) medicines, multivitamin, and food supplement it markets are duly licensed by the Philippine Food and Drug Administration (FDA). These assure the utmost safety of the market.  Latest Post 18 Mar 2025 JMN Brothers Pharma Limited Inc. 18 Mar 2025 Delex Pharma International Inc. 18 Mar 2025 DLX Holdings Corp. Popular Categories Strategic Partnerships Regulatory Approvals and Certifications Post-Merger Developments Mergers and Acquisitions Financial Performance Expansion Plans Community Engagement and Outreach OUR SUBSIDIARIES Current Operational Subsidiaries DLX Holdings Corp. DLX Holdings Corp., (DLX) the subsidiary of our company, was registered in December 2012, and is the parent company of Delex Pharma International Inc. (DPI). DLX is engaged in the development, distribution and trading of medical supplies, equipment, pharmaceutical products, and food supplements. Read More Delex Pharma International Inc. Delex Pharma International, Inc. (DPI), a socially accountable Filipino-owned and ISO 9001:2015-certified company, has continuously served its nationwide market for fourteen years. The company is 60% owned by DLX Holdings, Inc. and 40% owned by High Everest Capital Inc. rEAD mORE JMN Brothers Pharma Limited Inc. JMN Brothers Pharma Limited, Inc., a subsidiary company of Delex Pharma, was founded in the Philippines on June 27, 2016, by the management heading the latter organization. Although it is a new player in the market, it has slowly made rounds to become one of the trusted companies in the country, focusing on women’s health and ethical products. Read More

Delex Pharma International Inc.

Delex Pharma International Inc. admin_bncm Delex Pharma International Inc. Delex Pharma International, Inc. (DPI), a socially accountable Filipino-owned and ISO 9001:2015-certified company, has continuously served its nationwide market for fourteen years. The company is 60% owned by DLX Holdings, Inc. and 40% owned by High Everest Capital Inc. The profound ideas of venturing into the pharmaceutical industry from its competent award-winning leaders commenced on July 13, 2009. They continued to expand, establishing more businesses in medical devices and retail pharmacy (with three branches). DPI offers cost-effective and quality ICU drugs and medical devices manufactured by GMP-certified multinational companies (list and copy of agreements included in the index). It distributes and promotes various products in the critical care, anesthesia, medical devices, and oncology fields, housed in its government-compliant warehouses with a total lot area of 1,224 square meters. Meanwhile, as the company strives for excellence in meeting the gaps in critical care, it has gained the trust of its clients in the hospital channels, drug chains, and diagnostic laboratories.Furthermore, DPI continues to nurture its almost two hundred (200) employees. Latest Post 18 Mar 2025 JMN Brothers Pharma Limited Inc. 18 Mar 2025 Delex Pharma International Inc. 18 Mar 2025 DLX Holdings Corp. Popular Categories Strategic Partnerships Regulatory Approvals and Certifications Post-Merger Developments Mergers and Acquisitions Financial Performance Expansion Plans Community Engagement and Outreach OUR SUBSIDIARIES Current Operational Subsidiaries DLX Holdings Corp. DLX Holdings Corp., (DLX) the subsidiary of our company, was registered in December 2012, and is the parent company of Delex Pharma International Inc. (DPI). DLX is engaged in the development, distribution and trading of medical supplies, equipment, pharmaceutical products, and food supplements. Read More Delex Pharma International Inc. Delex Pharma International, Inc. (DPI), a socially accountable Filipino-owned and ISO 9001:2015-certified company, has continuously served its nationwide market for fourteen years. The company is 60% owned by DLX Holdings, Inc. and 40% owned by High Everest Capital Inc. rEAD mORE JMN Brothers Pharma Limited Inc. JMN Brothers Pharma Limited, Inc., a subsidiary company of Delex Pharma, was founded in the Philippines on June 27, 2016, by the management heading the latter organization. Although it is a new player in the market, it has slowly made rounds to become one of the trusted companies in the country, focusing on women’s health and ethical products. Read More

DLX Holdings Corp.

DLX Holdings Corp. admin_bncm DLX Holdings Corp. DLX Holdings Corp., (DLX) the subsidiary of our company, was registered in December 2012, and is the parent company of Delex Pharma International Inc. (DPI). DLX is engaged in the development, distribution and trading of medical supplies, equipment, pharmaceutical products, and food supplements. DLX is a Philippine based pharmaceutical company ranking 3rd in the hospital channel with a growth rate of 12.2% and ranked 49th in the Philippine pharmaceutical industry based on the IQVIA Mat Ref Dec 2020 Report. Share this : Latest Post 18 Mar 2025 JMN Brothers Pharma Limited Inc. 18 Mar 2025 Delex Pharma International Inc. 18 Mar 2025 DLX Holdings Corp. Popular Categories Strategic Partnerships Regulatory Approvals and Certifications Post-Merger Developments Mergers and Acquisitions Financial Performance Expansion Plans Community Engagement and Outreach OUR SUBSIDIARIES Current Operational Subsidiaries DLX Holdings Corp. DLX Holdings Corp., (DLX) the subsidiary of our company, was registered in December 2012, and is the parent company of Delex Pharma International Inc. (DPI). DLX is engaged in the development, distribution and trading of medical supplies, equipment, pharmaceutical products, and food supplements. Read More Delex Pharma International Inc. Delex Pharma International, Inc. (DPI), a socially accountable Filipino-owned and ISO 9001:2015-certified company, has continuously served its nationwide market for fourteen years. The company is 60% owned by DLX Holdings, Inc. and 40% owned by High Everest Capital Inc. rEAD mORE JMN Brothers Pharma Limited Inc. JMN Brothers Pharma Limited, Inc., a subsidiary company of Delex Pharma, was founded in the Philippines on June 27, 2016, by the management heading the latter organization. Although it is a new player in the market, it has slowly made rounds to become one of the trusted companies in the country, focusing on women’s health and ethical products. Read More

BNCM Announcement: DELEX Expands ICU FORUM and Global Network of Healthcare Professionals

DELEX Pharma is proud to announce the continued expansion of its global healthcare training programs, including the highly successful DELEX ICU Forum, which has evolved from an in-person event to a dynamic online platform, now attracting nearly 200,000 healthcare professionals worldwide. This expansion reinforces DELEX’s unwavering commitment to improving healthcare outcomes and its leadership in the critical care space, while providing significant growth potential for investors.

BNCM Announcement: DELEX Pharma Strengthens Leadership in Healthcare with Robust Distribution Channels and Nationwide Reach

DELEX Pharma, a key player in the Philippine healthcare sector, continues to solidify its market leadership with a strategic focus on expanding and optimizing its distribution channels. With a comprehensive and rapidly growing distribution network, DELEX Pharma is well-positioned to capitalize on the increasing demand for high-quality pharmaceutical and medical products, driving both revenue growth and long-term market dominance.

BNCM Announcement DELEX Pharma Strengthens Market Position with Expanding Client Base and Strategic Partnerships

DELEX Pharma, a leading force in the Philippine healthcare market, continues to solidify its position as a dominant player in the pharmaceutical and healthcare sectors. With an expanding portfolio of high-profile clients, including nearly 700 hospitals nationwide, over 900 Mercury Drug branches, and a growing list of private clinics and medical professionals, DELEX Pharma is strategically positioned for exceptional growth and sustained market leadership.

BNCM Announcement: DELEX Pharma Expands into the Online Pharmacy Market in the Philippines, Leveraging the Booming E-Pharmacy Sector in Asia

DELEX Pharma is excited to announce its strategic expansion into the rapidly growing online pharmacy market in the Philippines, as part of a broader initiative to tap into the booming e-pharmacy sector across Asia. This expansion reflects the company’s ongoing commitment to improving patient access to healthcare products and services through innovative, digital-first solutions. With the Asian online pharmacy market expected to reach a value of $[insert market value] billion by [insert forecast year], DELEX Pharma is well-positioned to capture a share of this growing opportunity and drive substantial growth for patients and investors.

BNCM Announcement: DELEX Accelerates Market Leadership with Major Expansion into Medical Device Sector

DELEX Pharma, a dominant force in the Philippine healthcare market, is set to revolutionize the medical device industry through a strategic expansion that positions the company for explosive growth. Building on its solid foundation in the pharmaceutical sector, DELEX Pharma is now advancing into the rapidly growing medical device market, capitalizing on new partnerships and cutting-edge technology to deliver world-class healthcare solutions to a broader range of patients and healthcare providers.